Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127594021 | 12759402 | 1 | I | 20140808 | 20160907 | 20160919 | 20160919 | EXP | FR-HQ SPECIALTY-FR-2016INT000878 | INTERCHEM | SASSIER M, PEYRO-SAINT-PAUL L, CLARISSE B, LECONTE A, COQUEREL A, ALEXANDRE J, ET AL.. CHEMOTHERAPY (PLATINUM AND PEMETREXED) IN COMBINATION WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER INDUCES MAJOR GASTROINTESTINAL TOXICITY. J CLIN PHARM THER. 2016;41 (4):447-448 | 56.00 | YR | F | Y | 0.00000 | 20160919 | PH | FR | FR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127594021 | 12759402 | 1 | PS | CISPLATIN. | CISPLATIN | 1 | 90 MG, EVERY 3 WEEKS, [3 CYCLES] | D | 18057 | 90 | MG | ||||||||
127594021 | 12759402 | 2 | SS | CISPLATIN. | CISPLATIN | 1 | D | 18057 | |||||||||||
127594021 | 12759402 | 3 | SS | CISPLATIN. | CISPLATIN | 1 | D | 18057 | |||||||||||
127594021 | 12759402 | 4 | SS | PEMETREXED | PEMETREXED | 1 | 600 MG, EVERY 3 WEEKS, [3 CYCLES] | D | 0 | 600 | MG | ||||||||
127594021 | 12759402 | 5 | SS | PEMETREXED | PEMETREXED | 1 | D | 0 | |||||||||||
127594021 | 12759402 | 6 | SS | PEMETREXED | PEMETREXED | 1 | D | 0 | |||||||||||
127594021 | 12759402 | 7 | SS | ERLOTINIB | ERLOTINIB | 1 | 150 MG, QD | D | 0 | 150 | MG | ||||||||
127594021 | 12759402 | 8 | SS | ERLOTINIB | ERLOTINIB | 1 | Unknown | UNK | D | 0 | |||||||||
127594021 | 12759402 | 9 | SS | ERLOTINIB | ERLOTINIB | 1 | D | 0 | |||||||||||
127594021 | 12759402 | 10 | SS | APREPITANT. | APREPITANT | 1 | UNK | U | 0 | ||||||||||
127594021 | 12759402 | 11 | SS | VERAPAMIL | VERAPAMIL HYDROCHLORIDE | 1 | UNK | U | 0 | ||||||||||
127594021 | 12759402 | 12 | C | PREDNISOLONE. | PREDNISOLONE | 1 | UNK | U | 0 | ||||||||||
127594021 | 12759402 | 13 | C | ONDANSETRON | ONDANSETRON | 1 | UNK | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127594021 | 12759402 | 1 | Non-small cell lung cancer metastatic |
127594021 | 12759402 | 2 | Metastases to central nervous system |
127594021 | 12759402 | 3 | Disease progression |
127594021 | 12759402 | 4 | Non-small cell lung cancer metastatic |
127594021 | 12759402 | 5 | Metastases to central nervous system |
127594021 | 12759402 | 6 | Disease progression |
127594021 | 12759402 | 7 | Non-small cell lung cancer metastatic |
127594021 | 12759402 | 8 | Metastases to central nervous system |
127594021 | 12759402 | 9 | Disease progression |
127594021 | 12759402 | 10 | Antiemetic supportive care |
127594021 | 12759402 | 11 | Hypertension |
127594021 | 12759402 | 12 | Antiemetic supportive care |
127594021 | 12759402 | 13 | Antiemetic supportive care |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127594021 | 12759402 | LT |
127594021 | 12759402 | OT |
127594021 | 12759402 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127594021 | 12759402 | Asthenia | |
127594021 | 12759402 | Diarrhoea | |
127594021 | 12759402 | Drug interaction | |
127594021 | 12759402 | Nausea | |
127594021 | 12759402 | Renal failure | |
127594021 | 12759402 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127594021 | 12759402 | 1 | 20140806 | 0 | ||
127594021 | 12759402 | 4 | 20140806 | 0 | ||
127594021 | 12759402 | 7 | 201402 | 0 | ||
127594021 | 12759402 | 8 | 20140806 | 0 |